NUREXONE BIOLOGIC INC.

Press Releases NurExone Biologic Inc.

Equities

NRX

CA67059R1091

Market Closed - Toronto S.E. Other stock markets 20:45:24 28/05/2024 BST			5-day change	1st Jan Change
0.49 ^CAD	0.00%		0.00%	+66.10%

04-25	NurExone Biologic Announces OTCQB Listing And DTC Eligibility	MT
04-02	NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	05-17	AQ
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	04-25	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	04-22	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	04-19	AQ
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	04-02	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	03-27	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	03-22	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	03-15	AQ
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	03-08	AQ
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	03-01	AQ
NurExone’s Intellectual Property Portfolio Expands	02-20	AQ
NurExone Launches Licensing Efforts for ExoTherapy Platform	02-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer